{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:25:18Z","timestamp":1789629918048,"version":"build-2803163510"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T00:00:00Z","timestamp":1550275200000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"NIH","award":["AR42309"],"award-info":[{"award-number":["AR42309"]}]},{"name":"NIH","award":["AR064925"],"award-info":[{"award-number":["AR064925"]}]},{"name":"NIH","award":["AR065800"],"award-info":[{"award-number":["AR065800"]}]},{"DOI":"10.13039\/100001844","name":"Scleroderma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.imlet.2017.09.011","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T22:31:24Z","timestamp":1506637884000},"page":"9-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy"],"prefix":"10.1016","volume":"195","author":[{"given":"Swati","family":"Bhattacharyya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.imlet.2017.09.011_bib0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","article-title":"Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities","volume":"8","author":"Bhattacharyya","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"issue":"19","key":"10.1016\/j.imlet.2017.09.011_bib0010","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.imlet.2017.09.011_bib0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.imlet.2017.09.011_bib0020","doi-asserted-by":"crossref","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.imlet.2017.09.011_bib0025","doi-asserted-by":"crossref","first-page":"e0114017","DOI":"10.1371\/journal.pone.0114017","article-title":"Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts","volume":"10","author":"Johnson","year":"2015","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.imlet.2017.09.011_bib0030","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1093\/hmg\/ddt248","article-title":"A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci","volume":"22","author":"Martin","year":"2013","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.imlet.2017.09.011_bib0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-014-0484-x","article-title":"Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance","volume":"17","author":"Korman","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"issue":"8","key":"10.1016\/j.imlet.2017.09.011_bib0040","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/art.34490","article-title":"brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity","volume":"64","author":"Koumakis","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2017.09.011_bib0045","doi-asserted-by":"crossref","DOI":"10.1089\/wound.2017.0732","article-title":"Toll like receptor \u22124 signaling drives persistent fibroblast activation and prevents fibrosis resolution in scleroderma","author":"Bhattacharyya","year":"2017","journal-title":"Adv. Wound Care"},{"issue":"5","key":"10.1016\/j.imlet.2017.09.011_bib0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00281-015-0503-7","article-title":"Role of innate immune system in systemic sclerosis","volume":"37","author":"Fullard","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.imlet.2017.09.011_bib0055","first-page":"2010","article-title":"DAMPening inflammation by modulating TLR signalling","author":"Piccinini","year":"2010","journal-title":"Mediators Inflamm."},{"issue":"5","key":"10.1016\/j.imlet.2017.09.011_bib0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10409238.2015.1033511","article-title":"Advances in toll-like receptor biology: modes of activation by diverse stimuli","volume":"50","author":"Bryant","year":"2015","journal-title":"Crit Rev Biochem Mol"},{"issue":"7242","key":"10.1016\/j.imlet.2017.09.011_bib0065","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/nature07830","article-title":"The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex","volume":"458","author":"Park","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.imlet.2017.09.011_bib0070","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.33325","article-title":"A rare polymorphism in the gene for toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators","volume":"64","author":"Broen","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.imlet.2017.09.011_bib0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/imm.12260","article-title":"Serum amyloid A induces interleukin-6 in dermal fibroblasts via toll-like receptor 2, interleukin-1 receptor-associated kinase 4 and nuclear factor-kappaB","volume":"143","author":"O'Reilly","year":"2014","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.imlet.2017.09.011_bib0080","doi-asserted-by":"crossref","first-page":"e0110820","DOI":"10.1371\/journal.pone.0110820","article-title":"Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis","volume":"10","author":"Lakota","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.imlet.2017.09.011_bib0085","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5808\/GI.2013.11.4.224","article-title":"Receptor for advanced glycation endproducts (RAGE), its ligands, and soluble RAGE: potential biomarkers for diagnosis and therapeutic targets for human renal diseases","volume":"11","author":"Lee","year":"2013","journal-title":"Genom. Inf."},{"issue":"8","key":"10.1016\/j.imlet.2017.09.011_bib0090","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.embor.7400205","article-title":"HMGB1 is an endogenous immune adjuvant released by necrotic cells","volume":"5","author":"Rovere-Querini","year":"2004","journal-title":"EMBO Rep."},{"issue":"9","key":"10.1016\/j.imlet.2017.09.011_bib0095","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.bbapap.2014.06.017","article-title":"Interaction of S100A13 with C2 domain of receptor for advanced glycation end products (RAGE)","volume":"1844","author":"Rani","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"1-2","key":"10.1016\/j.imlet.2017.09.011_bib0100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bbadis.2005.03.014","article-title":"RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling","volume":"1741","author":"Chaney","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.imlet.2017.09.011_bib0105","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4598","article-title":"Chronic toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis","volume":"16","author":"Stifano","year":"2014","journal-title":"Arthritis. Res. Ther."},{"issue":"1","key":"10.1016\/j.imlet.2017.09.011_bib0110","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ajpath.2012.09.007","article-title":"Toll-like receptor 4 signaling augments transforming growth factor-beta responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma","volume":"182","author":"Bhattacharyya","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.imlet.2017.09.011_bib0115","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"6","key":"10.1016\/j.imlet.2017.09.011_bib0120","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/art.30318","article-title":"Interferon and alternative activation of monocyte\/macrophages in systemic sclerosis-associated pulmonary arterial hypertension","volume":"63","author":"Christmann","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2017.09.011_bib0125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1465-9921-10-126","article-title":"Inhibiting toll-like receptor 4 signaling ameliorates pulmonary fibrosis during acute lung injury induced by lipopolysaccharide: an experimental study","volume":"10","author":"He","year":"2009","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.imlet.2017.09.011_bib0130","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/art.38901","article-title":"Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis","volume":"67","author":"Takahashi","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.imlet.2017.09.011_bib0135","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/nm.4192","article-title":"Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice","volume":"22","author":"Liang","year":"2016","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.imlet.2017.09.011_bib0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ajpath.2011.09.019","article-title":"TLR4 activity is required in the resolution of pulmonary inflammation and fibrosis after acute and chronic lung injury","volume":"180","author":"Yang","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"232","key":"10.1016\/j.imlet.2017.09.011_bib0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008264","article-title":"FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling","volume":"6","author":"Bhattacharyya","year":"2014","journal-title":"Science translational medicine"},{"key":"10.1016\/j.imlet.2017.09.011_bib0150","doi-asserted-by":"crossref","first-page":"11703","DOI":"10.1038\/ncomms11703","article-title":"Tenascin-C drives persistence of organ fibrosis","volume":"7","author":"Bhattacharyya","year":"2016","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.imlet.2017.09.011_bib0155","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.imlet.2017.09.011_bib0160","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/art.27443","article-title":"MicroRNA-29, a key regulator of collagen expression in systemic sclerosis","volume":"62","author":"Maurer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2017.09.011_bib0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-016-0929-x","article-title":"MicroRNAs in fibrosis: opportunities and challenges","volume":"18","author":"O'Reilly","year":"2016","journal-title":"Arthritis. Res. Ther."},{"issue":"1","key":"10.1016\/j.imlet.2017.09.011_bib0170","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11926-014-0474-z","article-title":"Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis","volume":"17","author":"Bhattacharyya","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"issue":"7","key":"10.1016\/j.imlet.2017.09.011_bib0175","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/iub.493","article-title":"Fibronectin splice variants: understanding their multiple roles in health and disease using engineered mouse models","volume":"63","author":"White","year":"2011","journal-title":"IUBMB Life"},{"issue":"1\u20132","key":"10.1016\/j.imlet.2017.09.011_bib0180","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/19336918.2014.987587","article-title":"Tenascin-C. Form versus function","volume":"9","author":"Giblin","year":"2015","journal-title":"Cell Adhes. Migration"},{"issue":"3","key":"10.1016\/j.imlet.2017.09.011_bib0185","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1189\/jlb.1206730","article-title":"The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4","volume":"82","author":"Gondokaryono","year":"2007","journal-title":"J. Leukoc. Biol."},{"issue":"13","key":"10.1016\/j.imlet.2017.09.011_bib0190","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1074\/jbc.M100099200","article-title":"The extra domain A of fibronectin activates Toll-like receptor 4","volume":"276","author":"Okamura","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.imlet.2017.09.011_bib0195","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/art.30308","article-title":"Extra domain A of fibronectin primes leukotriene biosynthesis and stimulates neutrophil migration through activation of Toll-like receptor 4","volume":"63","author":"Lefebvre","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.imlet.2017.09.011_bib0200","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1164\/rccm.200708-1291OC","article-title":"An essential role for fibronectin extra type III domain A in pulmonary fibrosis","volume":"177","author":"Muro","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.imlet.2017.09.011_bib0205","doi-asserted-by":"crossref","first-page":"e102974","DOI":"10.1371\/journal.pone.0102974","article-title":"Regulation of the innate immune response by fibronectin: synergism between the III-1 and EDA domains","volume":"9","author":"Kelsh","year":"2014","journal-title":"PLoS One"},{"issue":"47","key":"10.1016\/j.imlet.2017.09.011_bib0210","doi-asserted-by":"crossref","first-page":"36255","DOI":"10.1074\/jbc.C110.176990","article-title":"The first type III repeat in fibronectin activates an inflammatory pathway in dermal fibroblasts","volume":"285","author":"You","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.imlet.2017.09.011_bib0215","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/path.4104","article-title":"The myofibroblast matrix: implications for tissue repair and fibrosis","volume":"229","author":"Klingberg","year":"2013","journal-title":"J. Pathol."},{"issue":"28","key":"10.1016\/j.imlet.2017.09.011_bib0220","doi-asserted-by":"crossref","first-page":"E5625","DOI":"10.1073\/pnas.1707054114","article-title":"Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival","volume":"114","author":"Gocheva","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.imlet.2017.09.011_bib0225","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nm.1987","article-title":"Tenascin-C is an endogenous activator of toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease","volume":"15","author":"Midwood","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.imlet.2017.09.011_bib0230","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1471-2474-12-164","article-title":"Tenascin-C induces inflammatory mediators and matrix degradation in osteoarthritic cartilage","volume":"12","author":"Patel","year":"2011","journal-title":"BMC Musculoskelet Disord."},{"issue":"5","key":"10.1016\/j.imlet.2017.09.011_bib0235","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4330\/wjc.v8.i5.340","article-title":"Tenascin C upregulates interleukin-6 expression in human cardiac myofibroblasts via toll-like receptor 4","volume":"8","author":"Maqbool","year":"2016","journal-title":"World J. Cardiol."},{"issue":"443","key":"10.1016\/j.imlet.2017.09.011_bib0240","doi-asserted-by":"crossref","first-page":"ra86","DOI":"10.1126\/scisignal.aaf3596","article-title":"Distinct microenvironmental cues stimulate divergent TLR4-mediated signaling pathways in macrophages","volume":"9","author":"Piccinini","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.imlet.2017.09.011_bib0245","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.brainres.2016.04.034","article-title":"Epidermal growth factor-like repeats of tenascin-C-induced constriction of cerebral arteries via activation of epidermal growth factor receptors in rats","volume":"1642","author":"Fujimoto","year":"2016","journal-title":"Brain Res."},{"issue":"11","key":"10.1016\/j.imlet.2017.09.011_bib0250","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.15252\/embr.201540337","article-title":"EGFR kinase activity is required for TLR4 signaling and the septic shock response","volume":"16","author":"Chattopadhyay","year":"2015","journal-title":"EMBO Rep."},{"issue":"9","key":"10.1016\/j.imlet.2017.09.011_bib0255","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/labinvest.2010.100","article-title":"Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury","volume":"90","author":"Hsu","year":"2010","journal-title":"Lab. Invest."},{"issue":"4","key":"10.1016\/j.imlet.2017.09.011_bib0260","doi-asserted-by":"crossref","first-page":"e0125793","DOI":"10.1371\/journal.pone.0125793","article-title":"Lipopolysaccharide (LPS)-induced biliary epithelial cell NRas activation requires epidermal growth factor receptor (EGFR)","volume":"10","author":"Trussoni","year":"2015","journal-title":"PLoS One"},{"issue":"31","key":"10.1016\/j.imlet.2017.09.011_bib0265","doi-asserted-by":"crossref","first-page":"9680","DOI":"10.1073\/pnas.1511794112","article-title":"Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal","volume":"112","author":"De","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"21","key":"10.1016\/j.imlet.2017.09.011_bib0270","doi-asserted-by":"crossref","first-page":"e89073","DOI":"10.1172\/jci.insight.89073","article-title":"Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity","volume":"1","author":"Lofgren","year":"2016","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.imlet.2017.09.011_bib0275","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nsmb.2756","article-title":"Splicing factor SRSF6 promotes hyperplasia of sensitized skin","volume":"21","author":"Jensen","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"10.1016\/j.imlet.2017.09.011_bib0280","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1161\/CIRCRESAHA.111.242057","article-title":"Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis","volume":"109","author":"Manetti","year":"2011","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.imlet.2017.09.011_bib0285","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1189\/jlb.1212662","article-title":"The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis","volume":"93","author":"Yang","year":"2013","journal-title":"J. Leukoc. Biol."},{"issue":"7413","key":"10.1016\/j.imlet.2017.09.011_bib0290","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nature11290","article-title":"Novel role of PKR in inflammasome activation and HMGB1 release","volume":"488","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2017.09.011_bib0295","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-immunol-030409-101323","article-title":"HMGB1 is a therapeutic target for sterile inflammation and infection","volume":"29","author":"Andersson","year":"2011","journal-title":"Annu. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.imlet.2017.09.011_bib0300","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1089\/ars.2015.6409","article-title":"Regulation of posttranslational modifications of HMGB1 during immune responses","volume":"24","author":"Tang","year":"2016","journal-title":"Antioxid. Redox Signal."},{"issue":"1","key":"10.1016\/j.imlet.2017.09.011_bib0305","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1084\/jem.20141318","article-title":"MD-2 is required for disulfide HMGB1-dependent TLR4 signaling","volume":"212","author":"Yang","year":"2015","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.imlet.2017.09.011_bib0310","doi-asserted-by":"crossref","first-page":"e001993","DOI":"10.1161\/JAHA.115.001993","article-title":"Necrotic myocardial cells release damage-associated molecular patterns that provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis in vivo","volume":"4","author":"Zhang","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.imlet.2017.09.011_bib0315","doi-asserted-by":"crossref","first-page":"916486","DOI":"10.1155\/2011\/916486","article-title":"Gradual increase of high mobility group protein b1 in the lungs after the onset of acute exacerbation of idiopathic pulmonary fibrosis","volume":"2011","author":"Ebina","year":"2011","journal-title":"Pulm. Med."},{"issue":"4","key":"10.1016\/j.imlet.2017.09.011_bib0320","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1165\/rcmb.2007-0330OC","article-title":"The role of high mobility group box1 in pulmonary fibrosis","volume":"39","author":"Hamada","year":"2008","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"3","key":"10.1016\/j.imlet.2017.09.011_bib0325","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1124\/jpet.114.222372","article-title":"High-mobility group box 1 mediates epithelial-to-Mesenchymal transition in pulmonary fibrosis involving transforming growth factor-beta1\/Smad2\/3 signaling","volume":"354","author":"Li","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.imlet.2017.09.011_bib0330","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.3892\/mmr.2017.6364","article-title":"HMGB1 induces lung fibroblast to myofibroblast differentiation through NFkappaBmediated TGFbeta1 release","volume":"15","author":"Wang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.imlet.2017.09.011_bib0335","doi-asserted-by":"crossref","first-page":"e1847","DOI":"10.1038\/cddis.2015.206","article-title":"Chop deficiency prevents UUO-induced renal fibrosis by attenuating fibrotic signals originated from Hmgb1\/TLR4\/NFkappaB\/IL-1beta signaling","volume":"6","author":"Zhang","year":"2015","journal-title":"Cell. Death. Dis."},{"issue":"5","key":"10.1016\/j.imlet.2017.09.011_bib0340","doi-asserted-by":"crossref","first-page":"e64373","DOI":"10.1371\/journal.pone.0064373","article-title":"High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of PI3 K\/Akt and JNK","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.imlet.2017.09.011_bib0345","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1189\/jlb.0306170","article-title":"S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules","volume":"81","author":"Foell","year":"2007","journal-title":"J. Leukoc. Biol."},{"issue":"4","key":"10.1016\/j.imlet.2017.09.011_bib0350","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.bbrc.2004.07.096","article-title":"S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature)","volume":"322","author":"Marenholz","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.imlet.2017.09.011_bib0355","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.yjmcc.2015.11.002","article-title":"Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs)","volume":"94","author":"Turner","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.imlet.2017.09.011_bib0360","doi-asserted-by":"crossref","first-page":"828354","DOI":"10.1155\/2013\/828354","article-title":"S100A8 and S100A9. DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease","volume":"2013","author":"Schiopu","year":"2013","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.imlet.2017.09.011_bib0365","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2016.07.015","article-title":"S100A8\/A9. From basic science to clinical application","volume":"167","author":"Pruenster","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.imlet.2017.09.011_bib0370","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1136\/annrheumdis-2013-205013","article-title":"Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8\/A9 as a novel possible marker for systemic sclerosis phenotype","volume":"73","author":"van Bon","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.imlet.2017.09.011_bib0375","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1136\/annrheumdis-2013-204516","article-title":"S100A4 amplifies TGF-beta-induced fibroblast activation in systemic sclerosis","volume":"74","author":"Tomcik","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.imlet.2017.09.011_bib0380","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1189\/jlb.2MR0316-117RR","article-title":"Molecular mechanisms of regulation of Toll-like receptor signaling","volume":"100","author":"Leifer","year":"2016","journal-title":"J. Leukoc. Biol."},{"issue":"32","key":"10.1016\/j.imlet.2017.09.011_bib0385","doi-asserted-by":"crossref","first-page":"22545","DOI":"10.1074\/jbc.M502900200","article-title":"Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses","volume":"281","author":"Warger","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.imlet.2017.09.011_bib0390","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.immuni.2006.12.005","article-title":"Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages","volume":"26","author":"Yang","year":"2007","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.imlet.2017.09.011_bib0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2012.12.008","article-title":"The role of glycoprotein 96 in the persistent inflammation of rheumatoid arthritis","volume":"530","author":"Huang","year":"2013","journal-title":"Arch. Biochem. Biophys."},{"issue":"10","key":"10.1016\/j.imlet.2017.09.011_bib0400","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/intimm\/dxs068","article-title":"PRAT4A-dependent expression of cell surface TLR5 on neutrophils, classical monocytes and dendritic cells","volume":"24","author":"Shibata","year":"2012","journal-title":"Int. Immunol."},{"issue":"11","key":"10.1016\/j.imlet.2017.09.011_bib0405","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/intimm\/dxn098","article-title":"A single base mutation in the PRAT4A gene reveals differential interaction of PRAT4A with Toll-like receptors","volume":"20","author":"Kiyokawa","year":"2008","journal-title":"Int. Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2017.09.011_bib0410","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.4049\/jimmunol.177.3.1772","article-title":"A protein associated with toll-like receptor 4 (PRAT4A) regulates cell surface expression of TLR4","volume":"177","author":"Wakabayashi","year":"2006","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.imlet.2017.09.011_bib0415","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.it.2012.05.002","article-title":"Dissecting negative regulation of Toll-like receptor signaling","volume":"33","author":"Kondo","year":"2012","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2017.09.011_bib0420","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11926-008-0034-5","article-title":"Scleroderma gene expression and pathway signatures","volume":"10","author":"Sargent","year":"2008","journal-title":"Curr. Rheumatol. Rep."},{"issue":"5","key":"10.1016\/j.imlet.2017.09.011_bib0425","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/jid.2011.472","article-title":"Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies","volume":"132","author":"Pendergrass","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"8","key":"10.1016\/j.imlet.2017.09.011_bib0430","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/jid.2013.130","article-title":"Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis","volume":"133","author":"Hinchcliff","year":"2013","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.imlet.2017.09.011_bib0435","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/jid.2009.318","article-title":"A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity","volume":"130","author":"Sargent","year":"2010","journal-title":"J. Invest. Dermatol."},{"issue":"8","key":"10.1016\/j.imlet.2017.09.011_bib0440","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/CCM.0b013e3181e7c5c9","article-title":"A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis","volume":"38","author":"Rice","year":"2010","journal-title":"Crit. Care Med."},{"issue":"11","key":"10.1016\/j.imlet.2017.09.011_bib0445","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jama.2013.2194","article-title":"Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial","volume":"309","author":"Opal","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.imlet.2017.09.011_bib0450","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fimmu.2013.00387","article-title":"Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases","volume":"4","author":"Savva","year":"2013","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.imlet.2017.09.011_bib0455","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1016\/j.bmcl.2008.04.058","article-title":"IRAK-4 inhibitors: part 1: a series of amides","volume":"18","author":"Buckley","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.imlet.2017.09.011_bib0460","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1016\/j.bmcl.2008.04.039","article-title":"IRAK-4 inhibitors Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding","volume":"18","author":"Buckley","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.imlet.2017.09.011_bib0465","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1016\/j.bmcl.2008.04.042","article-title":"IRAK-4 inhibitors Part III: a series of imidazo[1,2-a]pyridines","volume":"18","author":"Buckley","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.imlet.2017.09.011_bib0470","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3554","article-title":"Interfering with pH regulation in tumours as a therapeutic strategy","volume":"10","author":"Neri","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.imlet.2017.09.011_bib0475","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/wound.2014.0599","article-title":"Fibrinogen-Related proteins in tissue repair: how a unique domain with a common structure controls diverse aspects of wound healing","volume":"4","author":"Zuliani-Alvarez","year":"2015","journal-title":"Adv. Wound Care"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247817303218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247817303218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:34:37Z","timestamp":1759044877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247817303218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":95,"alternative-id":["S0165247817303218"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2017.09.011","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2017.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}